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Abstract. Cerebrovascular angiopathy affects late-onset Alzheimer’s disease (LOAD) brains by possibly increasing vascular
endothelial growth factor (VEGF). A expression, thereby stimulating endothelial cell proliferation and migration. Indeed, VEGF-
A gene upregulation, with increased VEGF-A protein content of reactive astrocytes and microglia, occurs in LOAD brains, and
neovascularization was observed one week after injecting amyloid-β (Aβ)1−42 into rat hippocampus. We have now found, with
cultured ‘normoxic’ normal adult human astrocytes (NAHAs), that fibrillar Aβ25−35 (an active Aβ1−42 fragment) or a cytokine
mixture (the (CM)-trio (interleukin [IL]-1β+interferon [IFN]-γ+tumor necrosis factor [TNF]-α), or pair (IFN-γ+TNF-α) like
those produced in LOAD brains) stimulates the nuclear translocation of stabilized hypoxia-inducible factor (HIF)-1α protein and
its binding to VEGF-A hypoxia-response elements; the mRNA synthesis for three VEGF-A splice variants (121, 165, 189); and
the secretion of VEGF-A165. The CM-trio was the most powerful stimulus, IFN-γ+TNF-α was less potent, and other cytokine
pairs or single cytokines or Aβ35−25 were ineffective. While Aβ25−35 did not change HIF-1β protein levels, the CM-trio
increased both HIF-1α and HIF-1β protein levels, thereby giving an earlier and stronger stimulus to VEGF-A secretion by
NAHAs. Thus, increased VEGF-A secretion from astrocytes stimulated by Aβ1−42 and by microglia-released cytokines might
restore angiogenesis and Aβ1−42 vascular clearance.
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INTRODUCTION
VEGF (vascular endothelial growth factor) is best
known as a hypoxia-inducible, secreted protein that ac-
tivates receptor protein tyrosine kinases on vascular en-
dothelial cells to stimulate angiogenesis. But that is not
all this important factor does. VEGF has also controls
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neurogenesis in the sub-granular layer of adult den-
tate gyrus, and correspondingly, memory formation,
the progressive failure of which is perhaps one of the
most distressing characteristics of Alzheimer’s disease
(AD) [1].
A possible involvement of VEGF in AD is suggested
by the VEGF-A gene being one of several genes upreg-
ulated, along with Aβ1−42 accumulation in AD brains
but not in age-matched normal brains [2,3]. Addition-
ally, Kalaria and colleagues [4] found prominent im-
munoreactive VEGF in clusters of reactive astrocytes
on blood vessel walls and in diffuse perivascular de-
posits of Aβ1−42 in the neocortices of AD brains, but
not in age-comparable normal brains. Because of this
correlation between VEGF expression and AD, it is im-
portant to find out what causes astrocytes to synthesize
VEGF, as this might have important consequences in
an AD brain.
The VEGF expression in the AD brain could be
caused by astrocytes reacting to local hypoxia,resulting
from accumulation of perivascular Aβ1−42, with the re-
sulting stabilization of hypoxia-inducible factor (HIF)-
1α protein and the nuclear translocation of HIF-1α ·
HIF-1β (ARNT1 or aryl hydrocarbon receptor nuclear
translocator1) to stimulate VEGF-A gene expression.
Alternatively accumulating Aβ1−42 peptides might di-
rectly stimulate astrocytes independently of hypoxia to
make VEGF. An Aβ1−42-related action is suggested
by the VEGF immunoreactivity in astrocytes and mi-
croglia and neovascularization that appear a week after
injecting Aβ1−42 into the normal rat hippocampus [5].
However, this week-long delay suggests that the inject-
ed Aβ1−42 did not directly stimulate VEGF-A expres-
sion in the hippocampal glial cells – the VEGF expres-
sion required some Aβ1−42-induced mediator(s). This
could have been the proinflammatory cytokines that are
well known to be produced by activated glial cells in
the Aβ1−42-accumulating AD brain [6,7].
Thus, the evidence for Aβ1−42 being able to stimu-
late directly VEGF expression is equivocal. Park and
Chae [8] have reported that Aβ1−42 did not stimulate
HN33 mouse neuroblastoma cells and neonatal rat as-
trocytes to make VEGF. On the other hand, Soucek and
coworkers [9], working with cultured nerve cell lines
and primary cortical neurons, reported that Aβ1−42 sta-
bilized HIF-1α, which in turn induced the formation
of HIF1-α · HIF1-β, the heterodimeric transcription
factor that stimulates the expression of the VEGF-A
gene [10–18]. To resolve this contradictory issue, we
have tested the VEGF-stimulating abilities of Aβ25−35
and of proinflammatory cytokine(s) with a culture mod-
el that is directly relevant to the adult human brain;
that is, phenotypically normal, proliferatively quies-
cent astrocytes from adult human temporal lobe cere-
bral cortex (NAHAs, normal adult human astrocytes).
We will show that the synthetic peptide Aβ25−35, an
Aβ1−42 surrogate whose physical and biological fea-
tures it preserves [19] stabilizes HIF-1αprotein without
affecting HIF-1β expression and stimulates the nucle-
ar translocation of the HIF-1α · HIF-1β heterodimer,
its binding to HRE DNA, the expression of VEGF-
A mRNA splice variants, and the secretion of VEGF-
A165, the major splice variant synthesized in NAHAs.
We will also show that the mixture of three proinflam-
matory cytokines notoriously produced in AD brains,
namely IL-1β+IFN-γ+TNF-α, which we have previ-
ously shown to strongly stimulate NAHAs to make ni-
tric oxide (NO) [20–23], not only synergistically stabi-
lizes HIF-1α protein but, unlike Aβ25−35, also increas-
es HIF-1β expression and consequently more strongly
stimulates VEGF-A165 secretion.
MATERIALS AND METHODS
Isolation and culture of phenotypically normal NAHAs
NAHAs were isolated from temporal lobe cerebral
cortex tissue fragments of five male patients (range:
18–38 years) with perforating head injuries due to mo-
torcycle accidents who underwent neurosurgery imme-
diately. The cells were promptly cultured and propagat-
ed as previously described in full detail [24–27]. The
cells of these pure cultures only expressed astrocyte-
specific markers such as glial fibrillary acid protein
and glutamine synthase. None of the cells expressed
neuronal (enolase), oligodendrocytes (galactocerebro-
side), microglia (CD-68), or endothelial cells (factor
VIII) markers. These astrocytes proliferated slowly
without added growth factors in 90% (v/v) Ham’s F-
12/MCDB 153 medium and 10% (v/v) heat-inactivated
fetal bovine serum. They stopped growing upon reach-
ing confluence. Under both proliferating and nonprolif-
erating conditions the NAHAs steadily expressed their
characteristic astrocyte markers – they were phenotyp-
ically “locked-in”. But serum remained a necessary
component of the medium and withdrawing it caused
the astrocytes to self-destruct by apoptosis. The as-
trocytes of confluent, proliferatively quiescent cultures
started cycling again when subcultured. Only astro-
cytes from the fourth to the eighth subculture were used
because the response of the cells to proinflammatory
cytokines or Aβ25−35 became erratic with further sub-
culturing.
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Experimental protocol
Since astrocytes do not normally proliferate in the
adult human brain, we studied the effects on VEGF-
A production and release by Aβ25−35, the reversed-
sequence Aβ35−25 or proinflammatory cytokine(s) us-
ing confluent, proliferatively quiescent, pure NAHA
cultures [24–27]. At “0-h”, some cultures served as
untreated controls, while others were treated with (i)
20 µM of either Aβ25−35 or the inactive Aβ35−25
(Bachem, Bubendorf, Switzerland) or (ii) IL-1β (20 ng
ml), TNF-α (20 ng ml), and IFN-γ (70 ng ml) (all from
PeproTech EC Ltd., London, UK) either administered
individually or in pairs or as a three cytokine mixture
(the CM-trio). These concentrations were previous-
ly shown to be non-cytotoxic and when administered
together in a trio to potently stimulate MAP kinases
and NO production in NAHAs [24–27]. Cultures were
sampled between 18 h and 72 h after the onset of each
treatment.
Expression of HIF-1α, HIF-1β (ARNT1), and
VEGF-A splice variants’ mRNAs assessed via RT-PCR
RNA was extracted using a total RNA extraction
kit, Perfect PureTM (5PRIME, Eppendorf Italia, Mi-
lan, Italy), according to the manufacturer’s instructions.
The RNA quality was corroborated via electrophoresis
of 1 µg of total RNA in 1% agarose gel 20 µg/ml ethid-
ium bromide for 1 h at 90 V. Reverse transcription of
0.5µg aliquots of total mRNA was carried out using the
Transcriptor High FidelityTM cDNA Synthesis Sam-
ple Kit (Roche Diagnostics, Milan, Italy) according to
the manufacturer’s directions. Briefly, mRNA aliquots
(0.5µg) were mixed with 2.5 µg oligo (dT)-18 primers,
heated for 10 min at 65◦C and then cooled on ice. To the
tube containing the template primer-mix, Transcriptor
High Fidelity Reverse Transcriptase Reaction Buffer
1X 8 mM MgCl2, 20 U Protector RNAse Inhibitor,
deoxynucleotide mix 1 mM each, DTT 5 mM, 10 U
Transcriptor High Fidelity Reverse Trascriptase were
then added. The reaction was next incubated for 30 min
at 45◦C and for 5 min at 85◦C. Specific primers for
human VEGF-A and glyceraldehyde-3-phosphate de-
hydrogenase (GADPH) were those previously report-
ed [28]. Specific primers for human HIF-1α and HIF-
1β (ARNT1) were designed using Primer3 software
(version 0.4.0 accessible in Internet) according to pub-
lished sequences from the GenBank, that is: HIF-1α,
5’-CCGCTGGAGACACAATCATA-3’ (sense) and 5’-
GCTTGCGGAACTGCTTTC-TA-3’ (antisense); HIF-
1β, 5’-TGGTTTGGCAGCACACTCTA-3’ (sense),
and 5’-TCCATTCCTGCATCTGTTCC-3’ (antisense).
Each primer spanned at least an exon-intron boundary.
The primers were made by Invitrogen (Paisley, UK). To
obtain a linear amplification range, serial dilutions of
cDNA preparations from NAHAs were PCR-amplified
for 15–30 cycles and the resulting products run on a
2% agarose gel for 90 min at 90 V and stained by
stirring with Syto 60 (Invitrogen) 1:20000 in RNAse-
DNAse-free water for 45 min. Standard curves for
each gene product were thus obtained. The PCR am-
plifications were processed with a DNA thermal cycler
(MiniCyclerTM, MJ Research, M-Medical S.r.l, Milan,
Italy) in a final volume of 25 µl containing 2.5 mM
MgCl2, 1.5 U of HotMasterTM Taq DNA polymerase
(Eppendorf), 0.2 mM dNTPs, 0.4µg of each primer, 1X
reaction buffer, and 2 µl of cDNA per reaction. There-
after, PCR amplifications were performed as follows:
VEGF-A, through 26 cycles of 95◦C for 30 s, 60◦C
for 1 min, and 72◦C for 1 min; HIF-1α and GADPH,
through 23 and 22 cycles, respectively, of 94◦C for
30 s, 55◦C for 1 min, and 72◦C for 1 min; HIF-1β,
through 25 cycles of 94◦C for 30 s, 60◦C for 10 s,
and 72◦C for 20 s. The final PCR products were elec-
trophoresed on 2% agarose gel in 1X tris-borate ED-
TA buffer for 90 min at 90 V, stained by stirring with
Syto 60 1:20000 in RNAse-DNAse-free water for 45
min, scanned in an OdisseyTM infrared imaging system
(Licor Biosciences, Inc.; Lincoln, NE), and the inte-
grated intensity of each specific band accurately quan-
tified (in arbitrary units) using proprietary software. To
permit semi-quantitative analysis GAPDH was utilized
as an internal control. Sequencing analyses validated
the identities of the PCR DNA products fragments (not
shown).
Western immunoblotting
At chosen time points, control and treated NAHAs
were scraped into cold PBS, sedimented at 200 g for
10 min, and homogenized in T-PERTM tissue pro-
tein extraction reagent (Pierce, Rockford, IL) contain-
ing a complete EDTA-free protease inhibitor cocktail
(Roche). The protein contents of the samples were
determined according to Bradford [29] using BSA as
standard. Equal amounts (10–20 µg) of protein from
the samples were heat-denatured for 10 min at 70◦C
in an appropriate volume of 1X NuPAGE LDS Sam-
ple Buffer supplemented with 1X NuPAGE Reducing
Agent (Invitrogen). The samples were next loaded on
a NuPAGE Novex 10% Bis-Tris polyacrylamide gel
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(Invitrogen). After electrophoresis in NuPAGE MOPS
SDS Running Buffer using the Xcell SureLockTM
Mini-Cell (Invitrogen) (50 min run-time at 200 V con-
stant), proteins were blotted onto nitrocellulose mem-
branes (0.2 µm; Pall Italia, Milan, Italy). To ensure
efficient and reproducible binding to the membrane,
transfer proceeded under low power (30 V constant)
for 1-h in 1X NuPAGE Transfer Buffer containing
10% methanol and 0.1% NuPAGE antioxidant. Mem-
branes were probed with rabbit anti-human VEGF-A
IgG polyclonal antibody (Santa Cruz Biotechnology;
Heidelberg, Germany) or rabbit anti-HIF-1α antibody
(Novus Biologicals, Littleton, CO) or anti-HIF-1β an-
tibody (Santa Cruz Biotechnology) or anti-lamin B1
antibody (Santa Cruz Biotechnology) at a final dilution
of 1 µg ml. Subsequent processing was carried out as
previously detailed [24–27]. Lamin B1 was used as the
loading control.
ELISA assay of VEGF-A
Cell-conditioned growth media were taken at 0-h,
18-h, 24-h, 48-h, and 72-h after the onset of exposure of
NAHA cultures to each individual cytokine or cytokine
pairs, CM-trio, or Aβ25−35 or Aβ35−25, and stored at
−80◦C to be subsequently assayed for their VEGF-A
content. This was done with a specific commercial
ELISA kit (PeproTech). The tests were carried out
according to the instructions of the manufacturer. The
sensitivity of the assays for VEGF-A was 16 pg ml.
ELISA for HIF-1α transcriptional activity
NAHAs nuclear proteins were extracted using a kit
from Panomics (Fremont, CA) and carried out as sug-
gested by the manufacturer. Protein content was de-
termined by the Bradford protein assay kit (Bio-Rad;
Milan, Italy). An ELISA kit from Panomics was used
to assess the hypoxia response element (HRE) DNA
binding of the nuclear-extracted HIF-1α transcription
factor. Briefly, to form the HIF-1α/HRE DNA com-
plex, 40µl of binding buffer master mix were incubated
with 10 µl of sample nuclear extract (0.5 µg/ml) in the
sample plates for 30 min at room temperature. From
each well of the sample plate, 45 µl were then trans-
ferred to the assay plate. To capture the HIF-1α/HRE
DNA complex, the assay plate was washed three times
with the provided buffer and the samples were incu-
bated with a primary antibody against HIF-1α for 1 h
at room temperature. After washing and incubation
with the secondary antibody, colorimetric signals were
then developed by adding a TMB substrate solution to
each well, and read with a MultiskanTM (Labsystems,
Finland) spectrophotometer at 450 nm.
Statistics
The data were analyzed using SigmaStat 3.5 Ad-
visory Statistics for Scientists (Systat Software, Rich-
mond, CA). For RT-PCRs, data were normalized to
GADPH and next analyzed by one-way ANOVA. For
immunoblotting, data were normalized to lamin B1 and
next analyzed by one-way ANOVA. Post hoc Holm-
Sidak’s test was used for multiple pair-wise compar-
isons. Null hypotheses were rejected when P > 0.05.
RESULTS
VEGF-A protein secreted into the NAHA-conditioned
growth medium
We could detect small amounts of VEGF-A released
into the medium by the untreated NAHAs (Fig. 1A,B).
When administered separately, IL-1β, TNF-α, or IFN-
γ did not significantly change the basal 72 h VEGF-A
secretion (P > 0.05 vs. controls [None]) (Fig. 1A). Of
the cytokine pairs tested only the TNF-α+IFN-γ could
increase VEGF-A secretion (P < 0.001 vs. controls).
However, the CM-trio (IL-1β+IFN-γ+TNF-α) was the
strongest stimulator of VEGF-A secretion by 72 h (P <
0.001 or < 0.002 vs. controls and all other cytokine[s]
treatments; Fig. 1A). Aβ25−35 by itself also significant-
ly, though less strongly, stimulated VEGF-A secretion
by 72 h (P < 0.001 vs. controls) (Fig. 1A). By con-
trast, the reverse-sequence Aβ peptide, Aβ35−25, was
ineffective (P > 0.05 vs. controls), which established
the specificity of the stimulatory action of Aβ25−35
(Fig. 1A).
The timings of the VEGF responses to Aβ25−35 and
the CM-trio are shown in Fig. 1B. The extracellular
VEGF-A level stimulated by the CM-trio started rising
after 18 h, and the level stimulated by Aβ25−35 started
rising after 24 h and then both rose steadily thereafter
(Fig. 1B). According to the areas under the three se-
cretion curves in Fig. 1B, the total amount of VEGF-A
secreted between 0 and 72 h by the CM-trio-stimulated
NAHAs was 289% higher than the amount secreted by
untreated cells and that by the Aβ25−35-treated NA-
HAs was 148% higher than that secreted by untreated
cells (in both instances P < 0.05 vs. untreated con-
trols) (Table 1). Then again, the total amount of VEGF-
A secreted by the CM-trio-treated NAHAs was 36%
more than the amount secreted by the Aβ25−35-treated
NAHAs and this difference was significant (P < 0.05)
(Table 1).
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Table 1
Total 0-to-72-h VEGF-A secretion by cultured NAHAs
Treatment Total VEGF-A secreted∗ % Change Levels of statistical significance∗∗
None 566 ± 135 - - - - - - - -
CM-trio 2203 ± 325 + 289% vs. None P < 0.05
Aβ25−35 1406 ± 232 + 148% vs. None − 36% vs. CM-trio P < 0.05 P < 0.05
∗Total VEGF-A secretion was obtained via the integral calculus of the surface areas (in mm2) under the secretion curves
in Fig. 1B. Points in the curves are expressed in pg ml−1 of the means± SEM of the samples, each assayed in triplicate,
from 25 untreated (None) cultures and 5–7 Aβ25−35- or CM-trio-treated cultures. One-way ANOVA analysis of the
complete data set provided an F value of 16.323 (P < 0.001).
∗∗Pair-wise comparisons were carried out using post-hoc Holm-Sidak’s test.
Fig. 1. (A) VEGF-A secretion from NAHAs was induced by Aβ25−35 by itself, by CM-trio, and by a TNF-α+IFN-γ pair, but not by any of the
other cytokine treatments shown nor by the reversed-sequence peptide Aβ35−25. Bars are the means ± SEMs of the values from 25 separate
untreated (None) cultures, 12 Aβ25−35-, 3 Aβ35−25-, 7 CM-trio-, and 3 individual cytokines- or cytokine pairs-treated cultures, each assayed
in triplicate. Analysis by ANOVA: F = 21.035, P < 0.001; pair-wise comparisons via post-hoc Holm-Sidak’s test: ∗P < 0.001 vs. None
(untreated controls), individual and paired cytokines (save TNF-α+IFN-γ); ∗∗P < 0.001 vs. TNF-α+IFN-γ; ∗∗∗P < 0.001 vs. Aβ25−35. (B)
Time-related effects of CM-trio and of Aβ25−35 on VEGF-A secretion by NAHA cultures. Levels of statistical significance: ANOVA: None
(untreated controls), F = 0.0795, P > 0.05; Aβ25−35 , F = 14.132, P < 0.001; CM-trio, F = 39.526, P < 0.001; pair-wise comparisons with
post hoc Holm-Sidak’s test, ∗P < 0.05 vs. 0-h levels; ∗∗P < 0.05 vs. 18-h levels; ∗∗∗P < 0.05 vs. 24 h levels; ∗∗∗∗P < 0.05 vs. 48 h levels.
CM-trio-induced increases in secreted VEGF-A at both 24 h and 72 h were significantly higher (t test, P < 0.05) than the surges caused by
Aβ25−35. For the total 0-to-72-h secretion of VEGF-A by the NAHAs see Table 1.
Thus, VEGF-A secretion by NAHAs was strongly
increased by either the CM-trio or Aβ25−35 experi-
mental treatments, but we did not know what VEGF-A
splice variants were secreted. To find this out we ana-
lyzed the proteins in NAHAs lysates via immunoblot-
ting.
VEGF-A splice variants in NAHAs lysates
The NAHAs expressed three protein splice vari-
ants of VEGF-A, i.e., VEGF-A121, VEGF-A165, and
VEGF-A189 (Fig. 2A). But, as expected, production
of one of them, in this case VEGF-A165, predominat-
ed. Indeed, to measure VEGF-A189 and VEGF-A121
in the immunoblots, it was necessary to load 4 to 5-
fold more NAHAs’ protein lysate than the usual 10–
20 µg into the gel lanes. Since about three quarters of
the total VEGF-A protein in the NAHAs lysates was
VEGF-A165, we focused our attention on it (Fig. 2A).
Thus, our immunoblot studies showed that the intra-
cellular VEGF-A165 protein level fell slightly but not
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Fig. 2. VEGF-A165 was the predominant splice variant protein secreted by NAHAs into the medium but its intracellular levels were not
significantly changed by exposure to the CM-trio or to Aβ25−35 . (A) Left, the predominant VEGF-A variant, VEGF-A165, was readily detected
in immunoblots, but VEGF-A189 and VEGF-A121, were detectable only after loading with 4 to 5-fold more lysate proteins than usual. An
immunoblot typical of those from 4 separate experiments is shown. Right, results of densitometric assessment of the integrated intensities (in
arbitrary units) revealed that ∼75% of the VEGF-A protein was VEGF-A165, on which we therefore focused our attention. Levels of statistical
significance: ANOVA: F = 86.048, P < 0.001; pair-wise comparisons with post hoc Holm-Sidak’s test, ∗, VEGF-A165 vs. VEGF-A189 or
VEGF-A121, P < 0.05; but VEGF-A189 vs. VEGF-A121, P > 0.05. (B) Left, Western immunoblots (WB) were set up loading 10-20 µg of
total protein lysates from untreated (0-h) or CM-trio- or Aβ25−35-exposed NAHAs sampled according to the experimental protocol. LC, loading
control (i.e., lamin B1). Right, results of corresponding densitometric evaluations of the VEGF-A165-specific bands expressed as integrated
intensities (in arbitrary units). Points in the curves are the means ± SEM of 5 experiments with 0-h values normalized to 1.0. No statistically
significant differences vs. 0-h levels could be detected (ANOVA: Aβ25−35, F = 0.230, P > 0.05; CM-trio, F = 0.970, P > 0.05).
significantly (−10% by 48 h vs. 0 h levels; P > 0.05)
in Aβ25−35-treated NAHAs, while it rose slightly, but
again not significantly (+25% by 48 h vs. 0 h lev-
els; P > 0.05) in CM-trio-treated NAHAs (Fig. 2B).
Thus, nearly all of the newly produced VEGF-A165
was rapidly released by NAHAs into the medium and
not significantly stored in the cytoplasm.
VEGF-A splice variant mRNAs in NAHAs
Alternative splicing of the VEGF-A RNA transcript
at the gene’s exons 6 and 7 is known to produce sev-
eral different mRNAs [30,31]. As expected from the
immunoblots, we found, using RT-PCR, that untreat-
ed NAHAs did indeed express three VEGF-A mRNA
transcripts corresponding to the above mentioned three
VEGF-A isoforms (Fig. 3).
We found in Aβ25−35-exposed NAHAs that by 72 h
the major VEGF-A165 and the minor VEGF-A189 mR-
NAs were significantly (P < 0.05) upregulated vs.
basal (0 h) values, whereas the minor VEGF-A121-
encoding mRNA did not undergo statistically signif-
icant (P > 0.05) changes between 24 h and 72 h
(Fig. 3A). In the CM-trio-exposed NAHAs, the levels
of the VEGF-A189, VEGF-A165, and VEGF-A121 mR-
NAs were all significantly increased (P < 0.05) over
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Fig. 3. An increased expression of the major VEGF-A165 and minor VEGF-A189 splice variant mRNAs was induced in either Aβ25−35-
or CM-trio-treated NAHAs. A) Left, typical RT-PCR of samples from untreated (0-h) and Aβ25−35-treated NAHAs. Right, results of the
semiquantitative densitometric analysis of RT-PCR bands using GAPDH as an internal control (in arbitrary units). Points on the curves are means
± SEMs of 4 separate experiments. Levels of statistical significance: ANOVA: VEGF-A189, F = 14.606, P = 0.001; VEGF-A165, F =
12.432, P > 0.001; VEGF-A121, F = 1.046, P > 0.05; pair-wise comparisons with post hoc Holm-Sidak’s test, ∗P < 0.05 vs. 0-time values.
B) Left, typical RT-PCR of samples from untreated (0-h) and CM-trio-treated NAHAs. Right, results of the semiquantitative densitometric analysis
of RT-PCR bands using GAPDH as an internal control (in arbitrary units). Points on the curves are means ± SEMs of 4 separate experiments.
Levels of statistical significance: ANOVA: VEGF-A189, F = 8.879, P < 0.001; VEGF-A165, F = 4.212, P = 0.022; VEGF-A121, F =
6.839, P = 0.004; pair-wise comparisons with post hoc Holm-Sidak’s test, ∗P < 0.05 vs. corresponding 0-time values.
basal (0 h) levels between 24 h and 48 h to fall there-
after (Fig. 3B). Thus, both Aβ25−35 and the CM-trio
significantly stimulated the mRNA expression of the
major splice variant, VEGF-A165.
HIF-1α and HIF-1β (ARNT1) mRNA and protein
expression in NAHAs
We then asked whether Aβ25−35 and the CM-trio
could stimulate VEGF-A165 like hypoxia by simply
stabilizing HIF-1α and thus enabling the formation of
HIF-1α · HIF-1β (ARNT1) transcription factor het-
erodimer [10–13,32,33] or did they stimulate the HIF-
1α and/or HIF-1β gene or directly the VEGF-A gene.
Neither Aβ25−35 nor the CM-trio significantly
changed the basal HIF-1α (Fig. 4A) or HIF-1β mRNA
levels (Fig. 5A) in the NAHAs. Although they did not
affect the HIF-1α gene expression, they stimulated a
significant surge of HIF-1α protein between 0 h and
48 h (Fig. 4B). However, the CM-trio, but not Aβ25−35,
also significantly increased the HIF-1β protein level
in NAHAs at 24 h and 48 h (Fig. 5B). Thus, while
Aβ25−35 stabilized only the O2-sensitive HIF-1α pro-
tein, the CM-trio stabilized and augmented the levels
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Fig. 4. HIF-1α mRNA expression did not increase, while HIF-1α protein levels significantly increased, in the CM-trio- or Aβ25−35-treated
NAHAs. A) Left, typical RT-PCRs of samples from untreated or CM-trio- or Aβ25−35-treated NAHAs. Right, results of semiquantitative
densitometric analysis of RT-PCR bands (using GAPDH as an internal control) expressed as integrated intensities (in arbitrary units). Points in
the curves are the means ± SEM of 4 experiments with 0-time values normalized as 1.0. Levels of statistical significance: ANOVA: Aβ25−35,
F = 0.767, P > 0.05; CM-trio, F = 0.757, P > 0.05. However, the values of 24-h Aβ25−35 and 24-h CM-trio differed significantly from
each other (t test, ∗P = 0.021). B) Left, HIF-1α-specific protein bands in typical immunoblots (WB) of total protein lysates from untreated or
CM-trio- or Aβ25−35-treated NAHAs. LC, loading control (i.e., lamin B1). Right, results of densitometric appraisals of the integrated intensities
(in arbitrary units) of the HIF-1α specific bands vs. 0-h values that were normalized to 1.0. Points in the curves are the normalized means ±
SEM of the values from 5 distinct experiments. Levels of statistical significance: ANOVA: Aβ25−35, F = 22.796, P < 0.001; CM-trio, F =
12.897, P < 0.001; pair-wise comparisons with post hoc Holm-Sidak’s test, ∗P < 0.05 vs. 0-time; ∗∗P < 0.05 vs. corresponding 24-h value.
of both the HIF-1α and HIF-1β transcription factors in
the ‘normoxic’ NAHAs.
HIF-1α nuclear translocation and DNA binding at
HRE sites in NAHAs
We then found that Aβ25−35 or the CM-trio signif-
icantly stimulated the nuclear translocation and HRE
DNA binding of the HIF-1α, and therefore the HIF-
1α · HIF-1β heterodimer, in the NAHAs (Fig. 6).
The nuclear HRE DNA-bound HIF-1α level peaked
around 24 h with the Aβ25−35-driven translocation be-
ing slightly slower than the CM-trio-driven translo-
cation (Fig. 6). But then the nuclear levels of HIF-
1α in both the Aβ25−35- and CM-trio-treated NAHAs
dropped rapidly to the starting level by 48 h. Thus,
the reason for the CM-trio’s superior ability to stim-
ulate VEGF-A165 production and secretion, as shown
in Fig. 1, could consist in the ability of the CM-trio
to stabilize and hence increase both HIF-1α and HIF-
1β levels (Figs 4B and 5B) and, therefore, boost the
flow of VEGF-A gene-activating HIF-1α · HIF-1β het-
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Fig. 5. HIF-1β (ARNT1) mRNA expression did not increase, while HIF-1β protein levels rose in CM-trio- but not in Aβ25−35-treated NAHAs.
A) Left, typical RT-PCRs of samples from untreated or CM-trio- or Aβ25−35-treated NAHAs are shown. Right, results of semiquantitative
densitometric analysis of specific RT-PCR bands using GAPDH as an internal control expressed as integrated intensities (in arbitrary units).
Points in the curves are the means ± SEM of 4 experiments with 0-h values normalized as 1.0. Levels of statistical significance: ANOVA:
Aβ25−35, F = 0.591, P > 0.05; CM-trio, F = 0.360, P > 0.05. B) Left, HIF-1β (ARNT1)-specific protein bands in typical immunoblots
(WB) set up with total NAHAs’ protein lysates from untreated or CM-trio- or Aβ25−35-treated NAHAs. LC, loading control (i.e., lamin B1).
Right, results of densitometric assessment of the changes in intensity of HIF-1β-specific bands expressed as integrated intensities in arbitrary
units vs. 0-h values that were normalized to 1.0. Points in the curves are the means ± SEMs of 5 separate experiments. Levels of statistical
significance: ANOVA: Aβ25−35, F = 2.557, P > 0.05; CM-trio, F = 51.918, P < 0.001; pair-wise comparisons with post hoc Holm-Sidak’s
test, ∗P < 0.05 vs. corresponding 0-time values.
erodimers into the nucleus.
DISCUSSION
The present results obtained with relatively ‘normox-
ic’ NAHA cultures indicate that the VEGF-A produc-
tion by astrocytes in AD brains, but not age-matched
normal brains [6], need not be due just to hypoxia [4,
34–36], but also to the direct actions of Aβ peptides
and the ensemble of cytokines accumulating in the in-
flammatory environment of these brains. Yet these
agents acted like hypoxia by stimulating the formation
and nuclear translocation of the HIF-1α · HIF-1β het-
erodimers. Surprisingly, unlike the Aβ1−42 surrogate
Aβ25−35, none of the three members of the cytokine
trio could by itself significantly stimulate VEGF-A pro-
duction by cultured NAHAs – they had to work togeth-
er to induce the strongest stimulus of VEGF-A produc-
tion and release. However, the TNF-α+IFN-γ pair did
stimulate VEGF-A release, though less strongly than
the trio. In previous work by Argaw et al. [37], a differ-
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Fig. 6. The nuclear translocation and HRE DNA binding of HIF-1α
protein was significantly increased in NAHAs exposed to either
Aβ25−35 or the CM-trio. Points in the curves are the means± SEM
of 4 separate experiments with 0-h values normalized to 1.0. Levels
of statistical significance: ANOVA: Aβ25−35, F = 15.902, P <
0.001; CM-trio, F = 28.903, P < 0.001; pair-wise comparisons
withpost hoc Holm-Sidak’s test, ∗P < 0.05 vs. corresponding 0-time
values.
ent cytokine pair, for example IL-1β+IFN-γ was found
to stimulate VEGF-A secretion by normal fetal human
astrocytes more efficiently than either IL-1β or IFN-γ
given individually (the CM-trio was not tested). Even
IL-1β by itself was a weaker yet effective stimulator
in such cells. The divergence of our present findings
from those of Argaw et al. [37] clearly implies that
the modulation of VEGF-A production on the part of
proinflammatory cytokines changes significantly as the
normal fetal human astrocyte matures into an adult cell.
Hence, caution should be advisable in extrapolating the
cytokine-induced stimulatory mechanisms from fetal
to adult human astrocytes.
Thus, both Aβ25−35 and the CM-trio did stimulate
VEGF-A165 transcript expression and increased the
formation and nuclear translocation of HIF-1α · HIF-
1β heterodimers. But the question arises as to how
Aβ25−35 and the CM-trio could have stabilized HIF-
1α to produce HIF-1α · HIF-1β heterodimers in our
‘normoxic’ NAHA cultures. One possibility might be
the strong stimulation by the cytokine ensemble and by
Aβ25−35 of the expression of the NOS-2 (NO synthase-
2) gene and production of the proline hydroxylase-
inhibiting NO [24,25,38,39]. This NO certainly would
stabilize HIF-1α and enable HIF-1α · HIF-1β forma-
tion [40–43], but it happens too late [24,25]. Indeed,
the nuclear translocation of HIF-1α · HIF-1β to the
HRE DNA sites in the NAHAs peaked at 24 h, not 72 h,
as did the NO production in NAHA cultures (data not
shown; [24,25]). Clearly, it remains to be discovered
how Aβ25−35 by itself and the synergistically acting
members of the CM-trio stabilized HIF-1α in NAHAs.
Nevertheless, our results obtained with the cultured
NAHAs could explain the delayed VEGF response of
rat hippocampal astrocytes to injected Aβ1−42 report-
ed by Zand et al. [5] – they had to wait for the inject-
ed Aβ1−42 to induce microglia to generate an inflam-
matory environment and release an effective cytokine
ensemble [7,20–23].
Finally, we should look at what an abnormal Aβ1−42-
and cytokines-driven VEGF-A production might do in
the proinflammatory environment of an AD brain. The
release of angiogenic VEGF-A from the astrocytes of
the neurobarrier-coupling units with their blood vessel-
attached end-feet [44,45] would be expected in an AD
brain to produce new blood vessels to reverse or at
least minimize the Aβ1−42-induced vascular damage
responsible for hypoxia, glucose shortages, breached
blood-brain barrier and failing Aβ1−42 drainage [33,
46–51]. But it may not do so,because hypoxic endothe-
lial cells in the hypoperfused regions of an AD brain
downregulate their MEOX-2 homeobox gene and its
GAX protein product [47,52]. This causes the endothe-
lial cells to upregulate the AFX1 forkhead transcrip-
tion factor that downregulates their anti-apoptogenesis
Bcl-XL gene by stimulating the BCL-6 transcription-
al repressor [52,53]. The downregulation of MEOX-2
homeobox gene and its GAX protein product also low-
ers the level of the Aβ1−42-clearing soluble LRP1 [47,
52]. Therefore, while the increased VEGF production
in an AD brain would indeed stimulate angiogenesis,
this could counterproductively produce dysfunction-
al blood vessels with endothelial cells unable to clear
Aβ1−42 and hyper-prone to apoptogenesis.
While VEGF-A is best known for its angiogenic
action, it has only recently been found to operate
as a major factor in the radial glial (astrocyte-like)
cell/vascular-based stem cell niche in the sub-granular
zone of the dentate gyrus [1,34]. There it links
angiogenesis and vascular endothelial cell-produced
brain-derived neurotrophic factor (BDNF) and BDNF-
stimulated adult neurogenesis to continuously supply
the new granular cells needed to start recording the
memory of novel polymodal inputs from the entorhinal
cortex [1,54]. Therefore, the increased expression of
VEGF-A by astrocytes in a normal brain or induced
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by Zand et al.’s [5] injection of Aβ1−42 into rat brains
might promote the survival and proliferation of neural
progenitor cells, as indicated by the response of hip-
pocampal neuronal progenitor cells to infusion of the
protein into the lateral ventricles of adult rats [55]. But
this may be unlikely in an AD brain with its elevated
VEGF-A expression, as Waldau and Shetty [56] report-
ed in their review of neural stem cells in AD brains
that the AD pathology would prevent any VEGF-A-
stimulated immature granule cells from differentiating
into mature granule cells.
In conclusion, these observations suggest that the ex-
pression of VEGF by astrocytes that has been shown
to occur in AD brains, but not normal aging brains, is
likely because of the astrocytes responding to local hy-
poxia due vascular damage by accumulating perivas-
cular Aβ1−42, as well as to the direct actions of accu-
mulating Aβ1−42 and proinflammatory cytokines from
activated microglia. The contribution of the VEGF to
the development of AD remains to be shown, but we
suggest that it is likely not trivial.
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